羅博特科(300757.SZ):截至目前新增訂單情況良好,在手訂單金額持續擴大
格隆匯7月4日丨羅博特科(300757.SZ)接受機構調研時表示,關於公司原主業情況方面,得益於下游行業技術路徑由PERC轉為TopCon,今年以來客户端TopCon的投資擴產增量突出,依託於公司在光伏電池自動化設備領域的領先技術、產品優勢,公司今年以來的訂單增速顯著,截至2022年年度報吿披露之日,公司的在手訂單金額約為人民幣12.17億元,此後,公司陸續又新增較多的訂單,達到披露標準的,公司亦進行相應的披露,總體來説,截至目前公司新增訂單情況良好,在手訂單金額持續擴大。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.